Information for "Security Tolerability and Pharmacokinetics regarding Mevidalen LY3154207 a Centrally Behaving Dopamine D1 ReceptorPositive Allosteric Modulator D1PAM within Balanced Topics"
From EECH Central
Basic information
| Display title | Security Tolerability and Pharmacokinetics regarding Mevidalen LY3154207 a Centrally Behaving Dopamine D1 ReceptorPositive Allosteric Modulator D1PAM within Balanced Topics |
| Default sort key | Security Tolerability and Pharmacokinetics regarding Mevidalen LY3154207 a Centrally Behaving Dopamine D1 ReceptorPositive Allosteric Modulator D1PAM within Balanced Topics |
| Page length (in bytes) | 3,449 |
| Page ID | 1415028 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Pingisrael67 (Talk | contribs) |
| Date of page creation | 09:54, 28 April 2024 |
| Latest editor | Pingisrael67 (Talk | contribs) |
| Date of latest edit | 09:54, 28 April 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
